title: The role of cytokines in the changes in bone turnover following bone marrow transplantation.
abstract: Osteoporosis is a common disease among patients undergoing transplantation and a loss of bone mass is usually detected after bone marrow transplantation (BMT), particularly during the immediate post-BMT period. Post-BMT bone loss is primarily related to gonadal dysfunction and immunosuppression. Cytokines, especially interleukin 6, play an important role in the pathogenesis of postmenopausal osteoporosis. However, the pathogenetic role of cytokines in post-BMT bone loss is unknown and data on the changes of cytokines in accordance with bone turnover markers are scarce. The aim of this study was to assess the relationship between bone turnover markers and cytokines, which are regularly sampled at peripheral blood and bone marrow before and after allogeneic BMT. This prospective study included two analyses. The first was a study of 46 BMT recipients (M/F 28/18), examining the relationship between bone turnover markers and serum cytokines that were measured before and at 1 week, 2 weeks, 3 weeks, 4 weeks and 3 months after BMT. Serum intact parathyroid hormone was measured before BMT and at 3 weeks after BMT and its relation to other cytokines and bone turnover markers was evaluated. The second analysis was a study of 14 (M/F 9/5) of 46 patients in whom bone marrow plasma cytokines [interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha)] were measured at 3 weeks after BMT. The relationship between bone marrow plasma cytokines and bone turnover markers was studied because bone marrow is the microenvironment where the real changes in bone turnover occur. Serum type I collagen carboxyterminal telopeptide (ICTP), a bone resorption marker, increased progressively until 4 weeks (peak) after BMT and then decreased thereafter. Serum osteocalcin, a bone formation marker, decreased progressively until 3 weeks after BMT and then increased thereafter. Serum IL-6 increased until 2 weeks after BMT and declined thereafter. Serum TNF-alpha increased until 3 weeks after BMT and declined thereafter. There was a significant positive correlation between serum ICTP and bone marrow IL-6 levels at 3 weeks after BMT, when a marked change in bone metabolism occurs following BMT. However, a correlation between bone turnover markers and bone marrow TNF-alpha or peripheral blood cytokines was not found. At 3 months after BMT, there was a significant negative correlation between the mean daily steroid dose and the serum osteocalcin level (r = -0.43, p < 0.05). The correlation between the Mean daily steroid dose and serum ICTP was also significant (r = 0.41, p < 0.05). Our data suggest that the progressive increase in bone resorption during the immediate post-BMT period is related to both steroid dose and the increase in bone marrow IL-6, which is a potent stimulator of bone resorption in vivo.
authors.affiliation: Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul.
authors.forename: W Y
authors.initials: WY
authors.lastname: Lee
authors.forename: M I
authors.initials: MI
authors.lastname: Kang
authors.forename: E S
authors.initials: ES
authors.lastname: Oh
authors.forename: K W
authors.initials: KW
authors.lastname: Oh
authors.forename: J H
authors.initials: JH
authors.lastname: Han
authors.forename: B Y
authors.initials: BY
authors.lastname: Cha
authors.forename: K W
authors.initials: KW
authors.lastname: Lee
authors.forename: H Y
authors.initials: HY
authors.lastname: Son
authors.forename: S K
authors.initials: SK
authors.lastname: Kang
authors.forename: C C
authors.initials: CC
authors.lastname: Kim
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016723:Bone Remodeling / Q000187:drug effects / Q000502:physiology*; D016207:Cytokines / Q000502:physiology*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D015850:Interleukin-6 / Q000097:blood / Q000502:physiology; D008297:Male; D010024:Osteoporosis / Q000209:etiology* / Q000503:physiopathology; D011239:Prednisolone / Q000009:adverse effects; D011446:Prospective Studies; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000502:physiology
chemical_list: D015415:Biomarkers; D016207:Cytokines; D005938:Glucocorticoids; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone